CASE REPORT

J Clin Res Pediatr Endocrinol 2010; 2: -
Received Date:
Accepted Date:
*

Familial Glucocorticoid Deficiency Type 2: A Case Report - Case Report

 

ABSTRACT
Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease resulting from resistance to the action of adrenocorticotropic hormone (ACTH) on the adrenal cortex, which leads to isolated glucocorticoid deficiency with normal mineralocorticoid secretion.  It may present in infancy or early childhood with hyperpigmentation, failure to thrive, recurrent infections, hypoglycemic attacks and convulsions that may result in coma or death. Laboratory investigations reveal low cortisol and androgen levels with high ACTH associated with normal renin-aldosterone axis. The disorder may be caused by mutations in the gene of ACTH receptor (MC2R), or mutations in the newly described melanocortin-2 receptor accessory protein (MRAP) namely, FGD type 1 and FGD type 2, respectively. Twenty five percent of FGD cases are due to the mutations of the ACTH receptor, while FGD type 2 accounts for approximately 15-20% of FGD cases. Here, we report a six-month-old male infant, who presented with recurrent hypoglycemic convulsions. Serum hormone analysis showed low cortisol and androgen levels associated with a high ACTH concentration. No mutation was found in the NR0B1 and MC2R genes excluding congenital adrenal hypoplasia and FGD type 1. We found a homozygous deletion (c. 106+1delG) in intron 3 of MRAP gene. To our knowledge, this is the first Turkish patient reported with FGD type 2 due to a known MRAP mutation.
Key words: Familial glucocorticoid deficiency, ACTH unresponsiveness, MRAP

Conflict of interest: None declared
Received: 15.04.2010 Accepted: 08.06.2010

DOI: 10.4274/jcrpe.v2i3.122


 

 

Introduction

Familial glucocorticoid deficiency (FGD), or hereditary unresponsiveness to adrenocorticotropic hormone (ACTH), is a rare autosomal recessive disease characterized by glucocorticoid deficiency in the absence of mineralocorticoid deficiency. Mutations of the ACTH receptor, also known as the melanocortin-2 receptor (MC2R), account for approximately 25% of FGD cases (1). More recently, Metherell et al (2) demonstrated that mutations in melanocortin-2 receptor accessory protein (MRAP), encoding a new interacting partner of the ACTH receptor, caused FGD in 19 of 104 kindreds with confirmed FGD and no ACTH receptor mutations, and they account for a further 15–20% of FGD cases.
In the current paper, we describe the first Turkish patient with FGD type 2 due to a known MRAP mutation.

Case Report

A male baby was referred to our clinic for evaluation of hypoglycemic convulsions at the age of six months. He was born to consanguineous parents after an uneventful pregnancy with a birth weight of 4750 g. Medical history revealed that he had had a convulsion on the first day of life and had been receiving antiepileptic treatment since then. While on antiepileptic treatment, he had convulsive episodes again on three different occasions. The etiology of the convulsions had not been evaluated before. He was the eighth child of the family. Four of his siblings, three males and one female, had died on the first day of their lives. The other three siblings, two males and a female, were reported to be healthy. The baby had a male cousin, who was diagnosed as a case of isolated cortisol deficiency (Figure 1).
On physical examination, length was 73 cm (97th percentile; SDS:+2), weight 8700 g (90th percentile; SDS:+1.4), and head circumference was 46 cm (97th percentile). Blood pressure was 90/60 mmHg. His mid-parental target height was 167 cm (10th percentile, SDS:-1). Examination of the external genitalia revealed a penis of normal length and bilaterally palpable testes in the scrotum. Hyperpigmentation of the skin was noted. There were no signs of alacrima or achalasia. Other examination findings were unremarkable. Blood chemistry results were: glucose: 63 mg/dL, Na: 140 mmol/L, K: 4 mmol/L, Cl: 109 mmol/L, ALT: 28 IU/mL, and AST: 30 IU/mL. Total blood count was normal. Serum hormone analyses showed the following: 17-OH progesterone: 0.01 ng/mL (0.03-0.9), androstenedione: 0.01 ng/mL (<0.1-0.17), DHEA-S: 3 ng/mL (50-480), cortisol: 0.6 µg/dL (2.8-23), ACTH:708 pg/mL (6-48), plasma renin activity (PRA): 57 ng/mL/hr (2.35-37), aldosterone: 801 pg/mL (50-900). The bone age, evaluated by X-ray of the   left hand and wrist  according to the Greulich-Pyle atlas, was found to be equivalent to 9 months. Adrenal ultrasonography revealed that both adrenal glands were small in size -left: 6x8 mm, and right: 7x8 mm in diameter. Cranial ultrasonography was normal. Based on these findings, a diagnosis of isolated glucocorticoid deficiency was made, and oral hydrocortisone treatment at a dose of 10 mg/m2/d was started. 
For the molecular diagnosis, the entire coding region of the NR0B1 (DAX1), the MC2R gene and the 6 exons of the MRAP gene were amplified by PCR with intronic primers, and the PCR products on both the sense and antisense strand were sequenced. No mutation was found in the NR0B1 and MC2R genes. We found a homozygous deletion of one nucleotide at the canonical 5a donor splice site (c.106+1delG) in intron 3 of MRAP gene. The mutation was confirmed with a second independent PCR and  sequence reaction. The mother was found to be a heterozygous carrier for the 1-bp deletion in intron 3. 
On his most recent visit, at the age of four years and eight months, the patient had no hyperpigmentation. His height was 103 cm (25th percentile), weight 17 kg (25th percentile), testis volumes bilaterally were 2 ml with a penile length of 5 cm. The bone age was evaluated as 4 years.  His neurodevelopment was appropriate for age. The ACTH level was suppressed to slightly above the normal limit (53 pg/ml)  by 20 mg/m2/d oral hydrocortisone treatment. 
An informed consent for publication was taken from the mother.

Discussion

FGD is a rare autosomal recessive disorder characterized by isolated glucocorticoid deficiency in the absence of mineralocorticoid deficiency. These patients have low cortisol and high ACTH levels with a normal renin-aldosterone axis. FGD usually presents in infancy or in early childhood with hyperpigmentation, failure to thrive, recurrent infections, hypoglycemic attacks and convulsions that may result in coma or death (3). 
The differential diagnosis of adrenal insufficiency in infancy includes congenital disorders such as congenital adrenal hyperplasia, adrenal hypoplasia, adrenoleukodystrophy (ALD), ACTH resistance syndromes (FGD, Allgrove syndrome) and Kearns-Sayre syndrome; and acquired conditions such as adrenal hemorrhage, trauma and infections (4,5). 
Congenital adrenal hyperplasia was excluded by hormone analysis; acquired causes of adrenal insufficiency were also excluded by history and laboratory findings. Allgrove syndrome was not considered because of the absence of alacrima or achalasia. ACTH receptor gene sequences were normal in our patient excluding FGD type 1. Congenital adrenal hypoplasia was also unlikely, because he had well-developed genitalia and no mutation of the DAX1 gene. 
Mutations of ACTH receptor (MC2R) account for about 25% of FGD cases (FGD type 1, OMIM 202200) (1). 
Recently, mutations in MRAP gene, a gene encoding a small single transmembrane domain protein known as MRAP, have been described in a group of patients with ACTH resistance syndrome but with no mutations in MC2R gene (FGD type 2, OMIM 607398). MRAP, located at 21q22.1, is an essential cofactor for MC2R expression in certain cell types and seems to have a role in the processing, trafficking, or function of MC2R (2). MRAP has two isoforms, namely, MRAPa and MRAPb which differentially regulate the function of MC2R (6), and  so far 9 different mutations of MRAP in FGD patients have been described; they all result in either an absent or significantly truncated protein of both isoforms (7). MRAP mutations comprise approximately 20% of patients with FGD (2). In our patient, we found a 1-bp deletion at the canonical 5a donor splice site (c.106+1delG) in intron 3 of MRAP gene in the DNA of the patient in a homozygous state. His mother was heterozygous for the 1-bp deletion. In their study, Metherell et al (2) identified the 1-bp deletion, c. 106+1delG, in 6 individuals from 5 families with glucocorticoid deficiency, making this the second frequent mutation causing FGD unrelated to defects in the MC2R gene. To our current knowledge, 1-bp deletion (c. 106+1delG) in intron 3 of MRAP gene, identified in the DNA of the patient, can be regarded as the cause of FGD type 2.
In the only study regarding molecular diagnosis of FGD patients from Turkey, Berberoglu et al (8) reported 5 patients with FGD type 1. In this series, three siblings had homozygous V 142 L mutations and the other two siblings had homozygous D103N mutations in MC2R gene. To our knowledge, our patient is the first reported Turkish patient with FGD type 2, with a known MRAP mutation. The patient was the offspring of consanguineous parents and his four siblings had died in the neonatal period, probably due to glucocorticoid insufficiency. 
The long-term neurological consequences of FGD depend on the severity and number of hypoglycemic episodes during childhood. Modan-Moses et al (9) reported an Ethiopian infant, who presented with psychomotor retardation, spastic quadriparesis and microcephaly due to severe hypoglycemic attacks. They speculated that this phenotype could result from a novel MRAP mutation.
Our patient was diagnosed with FGD at the age of six months and had four convulsion episodes until presentation. Despite this history of several hypoglycemic attacks, at his most recent visit at age of four years and eight months, the patient’s neurodevelopment was appropriate for age.
Patients with FGD often have undetectable levels of adrenal androgens (10). In our patient also, 17-OH progesterone, androstenedione and DHEA-S levels were very low. 
Tall stature is observed in some FGD type 1 cases with MC2R mutations (11). Bone age was reported to be advanced in some of these patients, a finding, which was more pronounced before the initiation of treatment. It is reported that hydrocortisone replacement may decrease the height growth. Nevertheless, these children become tall adults (12). The excessive growth has been proposed to be due to high plasma ACTH levels (13). A possible mechanism for excessive growth is that all five melanocortin receptors are present in bone, and ACTH can stimulate cAMP production and gene expression in bone cells (11,14). 
Unlike FGD type1, FGD type 2 patients are known to be of normal height. At presentation, our patient’s length, weight, and head circumference percentiles were all above the parental target. Bone age was also advanced by three months. Although length in infancy may not reflect final height, we suggest that increased ACTH or related pathophysiologic changes might have caused advanced growth in this patient. After the initiation of treatment, anthropometric percentiles gradually decreased and came down to 25th percentile at age four years and eight months. On the most recent visit, it was observed that the bone age was delayed by about 8 months. The patient will be monitored closely for the effects of possible overdose of treatment.
FGD is characterized by isolated glucocorticoid deficiency in the presence of a normal renin-aldosterone axis. However, mild derangement of the renin-angiotensin system and mild salt-wasting at the time of diagnosis have been reported in some cases (12,15). In our patient, the initial PRA was also moderately elevated despite normal serum electrolyte levels. However, PRA and aldosterone levels on follow-up have remained within normal ranges. In these patients, definitive diagnosis can be made by finding mutations in the MC2R or recently described MRAP gene. Nevertheless, in about 55-60% of the FGD cases, the gene defect causing the disease has remained unidentified. 
In conclusion, clinical awareness of this condition is of considerable prognostic and therapeutic significance. 
Further studies describing new cases and mutations causing FGD will contribute to understanding the mechanism of this rare and potentially life-threatening disease.
Acknowledgement
The authors would like to thank Dr. Tim Strom (Institute of Human Genetics, Technical University Munich, Germany) for performing the genetic analyses on our patient and his mother)

Address for Correspondence: Leyla Akın, Erciyes University Faculty of Medicine Department of Pediatrics 55139, Kurupelit, Kayseri, Turkey Phone: +90 352 438 00 76  E-mail: leylabakin@gmail.com

References

1. Clark AJ, Metherell LA, Cheetham ME, Huebner A. Inherited ACTH insensitivity illuminates the mechanisms of ACTH action. Trends Endocrinol Metab 2005;16:451-457.
2. Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, Naville D, Begeot M, Khoo B, Nürnberg P, Huebner A, Cheetham ME, Clark AJ. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005;37:166-170.
3. Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. Journal of Clinical Endocrinology and Metabolism 2005;90:3243-3250.
4. Huebner A, Elias LL, Clark AJ. ACTH resistance syndromes. J Pediatr Endocrinol Metab 1999;(Suppl 1):277-293.
5. Akın L, Kurtoglu S, Kendirci M, Akın MA, Kardas F. Primary adrenal failure due to viral infection in an infant. Eur J Pediatr 2010;169:887-889.
6. Roy S, Rached M, Gallo-Payet N. Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. Molecular Endocrinology 2007;21:1656-1669.
7. 8 Chan LF, Clark AJL, Metherell LA.  Familial Glucocorticoid Deficiency: Advances in the Molecular Understanding of ACTH Action. Horm Res 2008;69:75-82.
8. Berberoğlu M, Aycan Z, Ocal G, Begeot M, Naville D, Akar N, Adiyaman P, Evliyaoglu O, Penhoat A. Syndrome of congenital adrenocortical unresponsiveness to ACTH. Report of six patients. J Pediatr Endocrinol Metab 2001;14:1113-1118.
9. Modan-Moses D, Ben Zeev B, Hoffmann C, Falik-Zaccai TC, Bental YA, Pinhas-Hamiel O, Anikster Y. Unusual presentation of familial glucocorticoid deficiency (FGD) with a novel MRAP mutation. J Clin Endocrinol Metab 2006;91:3713-3717.
10. Weber A, Clark AJ, Perry LA, Honour JW, Savage MO. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf) 1997;46:431-437.
11. Elias LL, Huebner A, Metherell LA, Canas A, Warne GL, Bitti ML, Cianfarani S, Clayton PE, Savage MO, Clark AJ. Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf) 2000;53:423-430. 
12. Clark AJ, Weber A. Adrenocorticotropin insensitivity syndromes. Endocr Rev 1998;19:828-843. 
13.  Imamine H, Mizuno H, Sugiyama Y, Ohro Y, Sugiura T, Togari H. Possible relationship between elevated plasma ACTH and tall stature in familial glucocorticoid deficiency. Tohoku J Exp Med 2005;205:123-131.
14. Zhong Q, Sridhar S, Ruan L, Ding KH, Xie D, Insogna K, Kang B, Xu J, Bollag RJ, Isales CM. Multiple melanocortin receptors are expressed in bone cells. Bone 2005;36:820-831.
15. Chan LF, Metherell LA, Krude H, Ball C, O'Riordan SM, Costigan C, Lynch SA, Savage MO, Cavarzere P, Clark AJ. Homozygous nonsense and frameshift mutations of the ACTH receptor in children with familial glucocorticoid deficiency (FGD) are not associated with long-term mineralocorticoid deficiency. Clin Endocrinol (Oxf) 2009;71:171-175.

Home Archive Search Menu